Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 12, 2008, Pages 1263-1268

  Wen, Shi Wu ^a,b   Zhou, Jia ^a,b,c   Yang, Qiuying ^a,b   Fraser, William ^d   Olatunbosun, Olufemi ^e   Walker, Mark ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; PHENOBARBITAL;

ADULT; ARTICLE; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL CARE; PLACENTAL DELIVERY; PREECLAMPSIA; PREGNANCY; SOLUTIO PLACENTAE;

EID: 57349193817     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080859     Document Type: Article

References (32)

1. Lambie DG, Johnson RH. Drugs and folate metablism. Drugs 1985;30:145-55.
2. US Food and Drug Administration, HHS. Requirements on content and format of labeling for human prescription drug and biological products. Fed Regist 2006;71:3921-97.
3. Wen SW, Walker M. Risk of fetal exposure to folic acid antagonists. J Obstet Gynaecol Can 2004;26:475-80.
4. Pastuszak A, Koren G, Milich V, et al. Prospective assessment of pregnancy outcome following first-trimester exposure to benzodiazepines. In: Koren G, editor. Maternal and fetal toxicology. New York (NY): Marcel Dekker; 1994. p. 77-88.
5. Bodnar LM, Tang G, Ness RB, et al. Periconceptional multivitamin use reduces the risk of preeclampsia. Am J Epidemiol 2006;164:470-7.
6. Hernandez-Diaz S, Werler MM, Louik C, et al. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. Am J Epidemiol 2002;156:806-12.
7. Wen SW, Chen XK, Rodger M, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008;198(1):45.e1-7.
8. Ray JG, Laskin C. Folic acid and homocycteine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999;20:519-29.
9. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775-81.
10. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary artery disease among women. JAMA 1998;279:359-64.
11. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;15:1042-50.
12. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-7.
13. Chambers JC, McGregor A, Jean-Marie J, et al. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998;351:36-7.
14. Ashworth JR, Warren AY, Johnson IR, et al. Plasma from pre-eclamptic women and functional change in myometrial resistance arteries. Br J Obstet Gynaecol 1998;105:459-61.
15. De Wolf F, Brosens I, Renaer M. Fetal growth retardation and the maternal arterial supply in the human placenta in the absence of sustained hypertension. Br J Obstet Gynaecol 1980;87:678-85.
16. Redman CWG. Current topic: pre-eclampsia and the placenta. Placenta 1991;12:301-8.
17. Roberts JM, Taylor RM, Goldfein A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700-8.
18. Giugliani ERJ, Jorge SM, Concalves AL. Serum vitamin B12 levels in parturients, in the intervillous space of the placenta and in full-term newborns and their relationships with folate levels. Am J Clin Nutr 1985;41:330-5.
19. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:961-6.
20. Kramer MS, Platt RW, Wen SW, et al.; Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001;108:E35.
21. Downey W, Beck P, McNutt M et al. Health databases in Saskatchewan. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chichester (UK): Wiley; 2000. p. 325-45.
22. Kramer MS, McLean FH, Boyd ME, et al. The validity of gestational age estimation by menstrual dating in term, preterm, and postterm gestations. JAMA 1988;260:3306-8.
23. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott Raven Publishers; 1998.
24. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2008;198:7-22.
25. ACOG Committee on Practice Bulletins - Obstetrics. ACOG practice bulletion. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159-67.
26. Krueger PM, Chang VW. Being poor and coping with stress: health behaviors and the risk of death. Am J Public Health 2008;98:889-96.
27. Conde-Agudelo A, Althabe F, Belizan JM, et al. Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. Am J Obstet Gynecol 1999;181:1026-35.
28. Williams JI, Young W. A summary on the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM, et al., editors. Patterns of health care in Ontario. The ICES practice atlas. 2nd ed. Ottawa (ON): Canadian Medical Association; 1996.
29. De Jong van den Berg LT, Feenstra N, Sorensen HT, et al. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. European Medicine and Pregnancy Group. Teratology 1999;60:33-6.
30. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995;333:201-5.
31. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14.
32. Hernandez-Diaz S, Werler MM, Walker AM, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-8.